Signal transducer and activator of transcription (STAT) (STAT)

The Signal transducer and activator of transcription (STAT) protein family consists of seven distinct transcription factors (STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, and STAT6) that play a pivotal role in the JAK-STAT signaling pathway (UniProt, 2024). These proteins are typically activated by Janus kinases (JAKs) in response to cytokine or growth factor stimulation, leading to their phosphorylation and subsequent dimerization (StatPearls, 2023). Once dimerized, STAT proteins translocate to the nucleus where they bind to specific promoter sequences to regulate the transcription of genes involved in cell growth, survival, and immune modulation (PubMed, 2022). In many human cancers, particularly STAT3 and STAT5 are constitutively active, driving tumor progression, metastasis, and resistance to apoptosis (NIH, 2023). Because of their central role in disease, STAT proteins are high-priority therapeutic targets, though their lack of a traditional enzymatic pocket makes them difficult to inhibit with small molecules (ClinicalTrials.gov, 2024). Current therapeutic strategies include the development of SH2 domain inhibitors, antisense oligonucleotides, and proteolysis-targeting chimeras (PROTACs) to disrupt their function or induce their degradation (PubMed, 2023).

Other names

STATsSignal transducers and activators of transcriptionSTAT family

Inhibition of SH2 domain-mediated dimerization, inhibition of DNA binding, antisense-mediated mRNA degradation, and targeted protein degradation (PROTACs) (PubMed, 2023).